Labcorp is trying to grow through specialty diagnostics, biopharma laboratory services, personalized health, and technology while managing pressure on traditional laboratory reimbursement. Its September 10, 2026 outlook targeted 5%–8% annual revenue growth and 8.5%–11.5% adjusted EPS growth through 2029, with margin expansion and cash-flow growth also expected.
The immediate signal is confirmation, not a reset. CMS’s preliminary Clinical Laboratory Fee Schedule rates point to significant PAMA-related pressure for 2027–2029, but Labcorp says that continuation of this pressure was already incorporated into the outlook issued 12 days earlier. 〔0〕
The new information is the policy detail, not a change in Labcorp’s plan. CMS has released preliminary rates and is still accepting public comment before finalizing them, so the filing does not quantify the eventual earnings impact or indicate that the company’s long-term targets need to change.
The risk is pushed into 2027 guidance rather than resolved. Labcorp says it is still evaluating the rates and will provide more detail when it issues 2027 financial guidance in February 2027. 〔1〕
Bottom line: This filing is a mixed update: reimbursement pressure looks real, but it was anticipated and does not currently force a change to Labcorp’s 2026–2029 outlook. The meaningful test moves to the February 2027 guidance.
Read the original 8-K on SEC EDGAR ↗